Lecanemab (BAN2401): an anti–beta-amyloid monoclonal antibody for the treatment of Alzheimer disease

References

• The Alzheimer’s Association. 2022 Alzheimer’s disease facts and figures. Alzheimers Dement. 2022;18(4):700–789.
   PubMed Web of Science ®Google Scholar
• Tamagno E, Guglielmotto M, Monteleone D, et al. The unexpected role of abeta1-42 monomers in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis. 2018;62(3):1241–1245.
   PubMed Web of Science ®Google Scholar
• Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401–a clinical study in Alzheimer’s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther. 2016;8(1):14.
   PubMedGoogle Scholar
• Siddiqi MK, Majid N, Malik S, et al. Amyloid oligomers. Protofibrils and fibrils. Subcell Biochem. 2019;93:471–503.
   PubMedGoogle Scholar
• Lord A, Gumucio A, Englund H, et al. An amyloid-beta protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol Dis. 2009;36(3):425–434.
   PubMed Web of Science ®Google Scholar
• Husna Ibrahim N, Yahaya MF, Mohamed W, et al. Pharmacotherapy of Alzheimer’s disease: seeking clarity in a time of uncertainty. Front Pharmacol. 2020;11:261.
   PubMed Web of Science ®Google Scholar
• Galimberti D, Scarpini E. Genetics and biology of Alzheimer’s disease and frontotemporal lobar degeneration. Int J Clin Exp Med. 2010;3(2):129–143.
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med. 2016;8(6):595–608.
   PubMed Web of Science ®Google Scholar
• Decourt B, D’Souza GX, Shi J, et al. The cause of alzheimer’s disease: the theory of multipathology convergence to chronic neuronal stress. Aging Dis. 2022;13(1):37–60.
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature. 2000;408(6815):982–985.
   PubMed Web of Science ®Google Scholar
• Nicoll JAR, Wilkinson D, Holmes C, et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat Med. 2003;9(4):448–452.
   PubMed Web of Science ®Google Scholar
• Zhao J, Nussinov R, Ma B. Mechanisms of recognition of amyloid-beta (Abeta) monomer, oligomer, and fibril by homologous antibodies. J Biol Chem. 2017;292(44):18325–18343.
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):322–333.
   PubMed Web of Science ®Google Scholar
• Zhang H, Gao Y, Zhao F, et al. Hydrogen sulfide reduces mRNA and protein levels of beta-site amyloid precursor protein cleaving enzyme 1 in PC12 cells. Neurochem Int. 2011;58(2):169–175.
   PubMed Web of Science ®Google Scholar
• Ohno M, Sametsky EA, Younkin LH, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer’s disease. Neuron. 2004;41(1):27–33.
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–372.
   PubMed Web of Science ®Google Scholar
• Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–321.
   PubMed Web of Science ®Google Scholar
• Sehlin D, Englund H, Simu B, et al. Large aggregates are the major soluble Abeta species in AD brain fractionated with density gradient ultracentrifugation. PLoS One. 2012;7(2):e32014.
   PubMed Web of Science ®Google Scholar
• Tolar M, Abushakra S, Hey JA, et al. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval. Alzheimers Res Ther. 2020;12(1):95.
   PubMed Web of Science ®Google Scholar
• Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer’s disease. N Engl J Med. 2021;384(18):1691–1704.
   PubMed Web of Science ®Google Scholar
• Tucker S, Moller C, Tegerstedt K, et al. The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575–588.
   PubMed Web of Science ®Google Scholar
• Sehlin D, Hedlund M, Lord A, et al. Heavy-chain complementarity-determining regions determine conformation selectivity of anti-abeta antibodies. Neurodegener Dis. 2011;8(3):117–123.
   PubMed Web of Science ®Google Scholar
• Alzforum. Therapeutics: lecanemab 2022 [Access Date 2022 Sept 8]. Available from: https://www.alzforum.org/therapeutics/lecanemab.
   Google Scholar
• Magnusson K, Sehlin D, Syvanen S, et al. Specific uptake of an amyloid-beta protofibril-binding antibody-tracer in AbetaPP transgenic mouse brain. J Alzheimers Dis. 2013;37(1):29–40.
   PubMed Web of Science ®Google Scholar
• Englund H, Sehlin D, Johansson AS, et al. Sensitive ELISA detection of amyloid-beta protofibrils in biological samples. J Neurochem. 2007;103(1):334–345.
   PubMed Web of Science ®Google Scholar
• Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Abeta protofibril formation. Nat Neurosci. 2001;4(9):887–893.
   PubMed Web of Science ®Google Scholar
• Lannfelt L, Söderberg L, Laudon H, et al. P4‐704: BAN2401 shows stronger binding to soluble aggregated amyloid‐beta species than aducanumab. Alzheimer’s &. Dementia. 2019;15(7S_Part_31):1601–1602.
   Google Scholar
• van Dyck Ch. Anti-amyloid-beta monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry. 2018;83(4):311–319.
   PubMed Web of Science ®Google Scholar
• Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Abeta protofibril antibody. Alzheimers Res Ther. 2021;13(1):80.
   PubMed Web of Science ®Google Scholar
• Satlin A, Wang J, Logovinsky V, et al. Design of a bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer’s disease. Alzheimers Dement. 2016;2(1):1–12.
   Google Scholar
• Sperling RA, Jack CR Jr., Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer’s Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7(4):367–385.
   PubMed Web of Science ®Google Scholar
• Penninkilampi R, Brothers HM, Eslick GD. Safety and efficacy of anti-amyloid-beta immunotherapy in Alzheimer’s disease: a systematic review and meta-analysis. J Neuroimmune Pharmacol. 2017;12(1):194–203.
   PubMed Web of Science ®Google Scholar
• Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with Alzheimer’s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241–249.
   PubMed Web of Science ®Google Scholar
• Budd Haeberlein S, O’Gorman J, Chiao P, et al. Clinical development of aducanumab, an anti-abeta human monoclonal antibody being investigated for the treatment of early Alzheimer’s disease. J Prev Alzheimers Dis. 2017;4(4):255–263.
   PubMed Web of Science ®Google Scholar
• van Dyck Ch, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21.
   PubMed Web of Science ®Google Scholar
• Aisen PS, Zhou J, Irizarry MC, et al. AHEAD 3‐45 study design: a global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer’s disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). Alzheimers Dement. 2020;16(S9):e044511.
   Google Scholar
• Eisai Inc. Eisai presents new findings on lecanemab’s investigational subcutaneous formulation and modeling simulation of APOE4 genotype on ARIA-E incidence at the Alzheimer’s Association International Conference (AAIC) 2022 [Access 2022 Sept 8]. Available from: https://www.eisai.com/news/2022/news202260.html
   Google Scholar
• Rofo F, Meier SR, Metzendorf NG, et al. A brain-targeting bispecific-multivalent antibody clears soluble amyloid-beta aggregates in Alzheimer’s disease. Mice Neurotherapeutics. 2022;19(5):1588–1602.
   PubMed Web of Science ®Google Scholar
• Johannesson M, Sahlin C, Soderberg L, et al. Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer’s disease. Mol Cell Neurosci. 2021;114:103641.
   PubMed Web of Science ®Google Scholar
• Eisai Inc. Eisai to present the latest lecanemab data, including ARIA-E and subcutaneous formulation, and other Alzheimer’s disease research at the Alzheimer’s Association International Conference (AAIC) 2022 [Access 2022 Sept 8]. Available from: https://www.prnewswire.com/news-releases/eisai-to-present-the-latest-lecanemab-data-including-aria-e-and-subcutaneous-formulation-and-other-alzheimers-disease-research-at-the-alzheimers-association-international-conference-aaic-2022-301592702.html
   Google Scholar